R. Sarangapani

Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

Jessie Gu, Adele Noè, Priya Chandra et al. · The Journal of Clinical Pharmacology · 2009 · 494 citations

Molecular Pharmacology, Hypertension, Heart Failure +11

Evaluation of the Potential Impact of Age- and Gender-Specific Pharmacokinetic Differences on Tissue Dosimetry 2Current address: Novartis Pharmaceuticals, East Hanover, NJ 07936.

Harvey J. Clewell, P. Robinan Gentry, Tammie R. Covington et al. · Toxicological Sciences · 2004 · 191 citations · Full text

Pharmacotherapy, Physiologically-based Pharmacokinetic Modeling, East Hanover +21

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF STYRENE AND STYRENE OXIDE RESPIRATORY-TRACT DOSIMETRY IN RODENTS AND HUMANS

R. Sarangapani, Justin Teeguarden, George Cruzan et al. · Inhalation Toxicology · 2002 · 82 citations

Unique Species Specificity, Physiologically-based Pharmacokinetic Modeling, Species Sensitivity +17

A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model

K. Melissa Hallow, Arthur Lo, Jeni Beh et al. · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · 2014 · 76 citations

Hypertension, Heart Failure, Hypertension Pathology +15

Evaluation of the Potential Impact of Age- and Gender-Specific Lung Morphology and Ventilation Rate on the Dosimetry of Vapors

R. Sarangapani, P. Robinan Gentry, Tammie R. Covington et al. · Inhalation Toxicology · 2003 · 73 citations

Asthma, Physiologically-based Pharmacokinetic Modeling, Dose Metrics +23